BrainStorm Cell Therapeutics announced that Nasdaq has halted trading of the company’s common stock. The U.S. FDA’s Cellular, Tissue and Gene Therapies Advisory Committee is meeting September 27 to review BrainStorm’s Biologics License Application for NurOwn for the treatment of amyotrophic lateral sclerosis. The ADCOM meeting is scheduled to take place 10:00 am to 6:00 pm ET.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCLI: